Insulet Corporate Adds Two New Board Members

Insulet Corporation has appointed Flavia Pease and Timothy Stonesifer to its Board of Directors. The pair replace Shacey Petrovic and Corinne Nevinny, who will retire from the board during the company’s 2024 Annual Meeting in May.
 
“We are excited to welcome Flavia and Tim to the Insulet Board,” Insulet Board Chairman Timothy Scannell said. “They are both highly respected leaders who have had distinguished careers and critical leadership roles in prominent corporations. We look forward to benefitting from their expertise and insights.”
 
Pease is corporate executive vice president and chief financial officer (CFO) at Charles River Laboratories, where she leads the Finance and Procurement functions. She joined Charles River in 2022. Before joining Charles River, Pease served in various leadership roles at Johnson & Johnson during her 23-year tenure, including vice president and group CFO of Johnson & Johnson’s global Medical Devices business, and vice president, Finance, for Janssen North America.

Pease earned a bachelor of science degree in economics from the Pontifícia Universidade Católica in Rio de Janeiro, Brazil, and an MBA from Santa Clara University.
 
As CFO at Alcon, Stonesifer has more than 30 years of global financial and operational experience. He has been the CFO at Alcon since April 2019. Prior to joining Alcon, he was executive vice president and CFO at Hewlett Packard Enterprise (HPE) from November 2015 through September 2018. Before joining HPE, he was CFO at General Motors’ International Operations from 2011 to 2014. Earlier in his career, Stonesifer served in various CFO roles at divisions of General Electric during his 21-year tenure.

Stonesifer earned a bachelor of arts degree in economics from the University of Michigan.
 
Petrovic, who has nearly six years of board service, joined Insulet in 2015 as chief commercial officer and served as president and CEO for more than three years. Nevinny is retiring from the board after serving for five years.
 
“As we say goodbye to Shacey Petrovic and Corinne Nevinny, we thank them for their contributions and dedication,” Scannell stated. “Shacey’s time with us is marked by her leadership, which has been instrumental to our growth trajectory. Her legacy, combined with Corinne’s significant insights and contributions, leaves a positive mark on our company’s journey.”
 
Headquartered in Massachusetts, Insulet Corporation has developed the Omnipod Insulin Management System, which provides an alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be fully controlled by a compatible personal smartphone or the Omnipod 5 Controller. Insulet also leverages the design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.